Estimation of the extent of oral absorption in animals from oral and intravenous pharmacokinetic data in drug discovery

Journal of Pharmaceutical Sciences

Volumn 98, Issue 11, 2009, Pages 4027-4038

  Nomeir, Amin A ^a   Morrison, Richard ^a   Prelusky, Daniel ^a   Korfmacher, Walter ^a   Broske, Lisa ^a   Hesk, David ^a   Mcnamara, Paul ^a   Mei, Hong ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Absorption; ADME; Bioavailability; Hepatic clearance; Oral absorption; Pharamcokinetics

Indexed keywords

DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG DELIVERY SYSTEM; MALE; NONHUMAN;

EID: 70349645327     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21705     Document Type: Article

References (34)

1. Amidon GL, Lennernas H, Shah PV, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
2. Johnson KC, Swindell AC. 1966. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res 13:1795-1798.
3. Norris DA, Leesman GD, Sinko PJ, Grass GM. 2000. Development of predictive pharmacokinetic simulation models for drug discovery. J Control Release 65:55-62.
4. Stenberg P, Bergstrom CAS, Luthman K, Artursson P. 2002. Theoretical predictions of drug absorption in drug discovery and development. Clin Pharmacokin 41:877-899.
5. Fung EN, Chu I, Li C, Liu T, Soares A, Morrison R, Nomeir AA. 2003. Higher-throughput screening for Caco-2 permeability utilizing a multiple sprayer LC-MS/MS system. Rapid Commun Mass Spectrom 17:2147-2152.
6. He X, Sugawara M, Kobayashi M, Takekuma Y, Miyazaki K. 2003. An in vitro system for prediction of oral absorption of relatively water-soluble drugs and ester prodrugs. Int J Pharm 263:35-44. (Pubitemid 37087930)
7. Krishna G, Chen KJ, Lin CC, Nomeir AA. 2001. Permeability of lipophilic compounds in drug discovery using in vitro human absorption model, Caco-2. Int J Pharm 222:77-89. (Pubitemid 32525789)
8. Taylor EW, Gibbons JA, Braeckman RA. 1997. Intestinal absorption screening of mixtures from combinatorial libraries in the Caco-2 Model. Pharm Res 14:572-577. (Pubitemid 27220273)
9. Wang Z, Hope CECA, Leung KH, Pang JM. 2000. Determination of in vitro permeability of drug candidates through a Caco-2 cell monolayer by liquid chromatography/tandom mass spectrometry. J Mass Spectrom 35:71-76. (Pubitemid 30060154)
10. Yamashita S, Tanaka Y, Endoh Y, Taki Y, Sakane T, Nadai T, Sezaki H. 1997. Analysis of drug permeation across Caco-2 monolayer: Implication for predicting in vivo drug absorption. Pharm Res 14:486-491. (Pubitemid 27205009)
11. Ertl P, Rohde B, Selzer P. 2000. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714-3717. (Pubitemid 30764293)
12. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approach to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 23:3-25. (Pubitemid 27046991)
13. Palm K, Stenberg P, Luthman K, Artursson P. 1997. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res 14:568-571. (Pubitemid 27220272)
14. Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P. 1998. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictions. J Med Chem 41:5382-5392. (Pubitemid 29031322)
15. Obata K, Sugano K, Saitoh R, Higashida A, Nabuchi Y, Machida M, Aso Y. 2005. Prediction of oral drug absorption in human by theoretical passive absorption models. Int J Pharm 293:183-192. (Pubitemid 40385116)
16. van de Waterbeemd H, Gifford E. 2003. ADMET in silico modeling: Toward prediction paradise? Nat Rev Drug Discov 2:192-204.
17. Gil C, Dorronsoro I, Castro A, Martinez A. 2005. Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neural network techniques. Bioorg Med Chem Lt 5:1919-1921. (Pubitemid 40380759)
18. Boxenbaum H. 1999. Absorption potential and its variants. Pharm Res 16:1893.
19. Griffiths R, Lewis A, Jeffrey P. 1996. Models of drug absorption in situ and in conscious animals. In: Borchardt R.T. et al. (Ed.), Models for assessing drug absorption and metabolism. New York Plenum Press.
20. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman J. 2004. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 47:4022-4031. (Pubitemid 38970963)
21. Wajima T, Fukumura K, Yano Y, Oguma T. 2003. Prediction of human pharmacokinetics from animal dataand molecular structural parameters using multivariate regression analysis: Oral clearance. J Pharm Sci 92:2427-2440. (Pubitemid 37484769)
22. Tse FL, Jaffe JM, Troendle A. 1992. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 32:630-638.
23. Rozman KK, Klaassen CD. 2001. Absorption, distribution, and excretion of toxicants. In: CD, Klaassen editor. Casarett and Doull's toxicology, the basic science of poisons. New York: McGraw Hill.
24. Barr WH, Lin CC, Radwanski E, Lim J, Symchowicz S, Affrime M. 1991. The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis 14:93-100.
25. Gibaldi M, Perrier D. 1982. Pharmacokinetics. 2nd edition. New York: Marcel Dekker. pp. 409-417.
26. Pollack GM, Brouwer KLR, Demby KB, Jones JA. 1990. Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green or galactose. Drug Metab Dispos 18:197-202.
27. Davies B, Morris T. 1993. Physiological parameters of laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
28. White RE. 2000. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Ann Rev Pharmacol Toxicol 40:133-157. (Pubitemid 30340676)
29. Chu I, Nomeir AA. 2006. Utility of mass spectrometry for in-vitro ADME assays. Curr Drug Metab 7:467-477.
30. Komura H, Iwaki M. 2008 Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 9:1775-1800.
31. Sakuda S, Akabane T, Teramura T. 2006. Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. Xenobiotica 36:331-340. (Pubitemid 43754758)
32. Takahashi M, Washio T, Suzuki N, Igeta K, Fujii Y, Hayashi M, Shirasaka Y, Yamashita S. 2008. Characterization of gastrointestinal drug absorption in cynomolgus monkeys. Mol Pharm 5:340-348. (Pubitemid 351579136)
33. Nishimura T, Amano N, Kubo Y, Ono M, Kato Y, Fujita H, Kimura Y, Tsuji A. 2007. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Drug Metab Dispos 35:1275-1284. (Pubitemid 47121767)
34. Dreyfuss J, Shaw JM, Ross JJ, Jr. 1978. Absorption of the beta-adrenergic-blocking agent, nadolol, by mice, rats, hamsters, rabbits, dogs, monkeys, and man: An unusual species difference. Xenobiotica 8:503-508.